轉(zhuǎn)錄因子Foxd3抑制Gab2基因表達及其誘導(dǎo)的肝癌發(fā)生
發(fā)布時間:2021-08-18 04:02
肝癌是導(dǎo)致癌癥疾病死亡的第二大因素,僅次于肺癌。亞洲已經(jīng)成為全世界肝癌患者數(shù)目最多的地區(qū),其中超過半數(shù)發(fā)生在中國。目前的治療手段并不能完全治愈肝癌,而針對肝癌患者的藥物也僅僅只有索拉菲尼被批準用于臨床治療。因此,進一步闡明肝癌發(fā)生的分子機制,對于了解這種疾病并開發(fā)出新的治療手段是非常必要的。作為腫瘤促進因子的Gab2,為針對肝癌靶向藥物的開發(fā)提供了新思路。Gab2在多種癌癥疾病中表現(xiàn)活躍,尤其是作為肝癌疾病中的促癌因子,其可以通過介導(dǎo)多種信號分子誘導(dǎo)肝炎的發(fā)病過程,并能夠被多種致病因素募集,整合肝臟疾病發(fā)生的多種調(diào)控信號,促進肝癌的發(fā)生與發(fā)展。因此,Gab2可能是一個肝臟疾病治療的潛在靶點,針對這個靶點有可能改變多種疾病的信號通路,從而有效逆轉(zhuǎn)疾病走向。我們從Gab2的基因轉(zhuǎn)錄入手,經(jīng)過分析和篩選,注意到了作為轉(zhuǎn)錄因子的Foxd3。與Gab2截然不同的是,Foxd3在多種癌癥中扮演抑制腫瘤發(fā)生與發(fā)展的重要角色。首先,我們利用EMSA實驗證實了Foxd3通過直接結(jié)合在Gab2的啟動子區(qū)來抑制Gab2基因的轉(zhuǎn)錄。接著,從不同層面對Foxd3和Gab2的表達水平的檢測結(jié)果表明,在肝癌疾病中,...
【文章來源】:廈門大學(xué)福建省 211工程院校 985工程院校 教育部直屬院校
【文章頁數(shù)】:97 頁
【學(xué)位級別】:碩士
【部分圖文】:
圖1-3丙型肝炎病毒的發(fā)病機制??Fig.1-3?The?pathogenesis?of?hepatitis?c?virus??
圖1-4酒精性肝病發(fā)展為肝癌的進程??
圖1-5非酒精性脂肪性肝病的發(fā)病機制??Fig.1-5?The?pathogenesis?of?nonalcoholic?fatty?liver?disease??
【參考文獻】:
期刊論文
[1]Targeted and immune therapies for hepatocellular carcinoma:Predictions for 2019 and beyond[J]. Masatoshi Kudo. World Journal of Gastroenterology. 2019(07)
[2]Hepatitis C virus core protein modulates several signaling pathways involved in hepatocellular carcinoma[J]. Shahab Mahmoudvand,Somayeh Shokri,Reza Taherkhani,Fatemeh Farshadpour. World Journal of Gastroenterology. 2019(01)
[3]Global elimination of hepatitis C virus infection: Progresses and the remaining challenges[J]. Reza Taherkhani,Fatemeh Farshadpour. World Journal of Hepatology. 2017(33)
[4]Functional interaction of endoplasmic reticulum stress and hepatitis B virus in the pathogenesis of liver diseases[J]. So Young Kim,Yi Yi Kyaw,Jaehun Cheong. World Journal of Gastroenterology. 2017(43)
[5]Role and regulation of the forkhead transcription factors FOXO3a and FOXM1 in carcinogenesis and drug resistance[J]. Ana R.Gomes,Fung Zhao,Eric W.F.Lam. Chinese Journal of Cancer. 2013(07)
[6]Adiponectin,a key adipokine in obesity related liver diseases[J]. Christa Buechler,Josef Wanninger,Markus Neumeier. World Journal of Gastroenterology. 2011(23)
本文編號:3349150
【文章來源】:廈門大學(xué)福建省 211工程院校 985工程院校 教育部直屬院校
【文章頁數(shù)】:97 頁
【學(xué)位級別】:碩士
【部分圖文】:
圖1-3丙型肝炎病毒的發(fā)病機制??Fig.1-3?The?pathogenesis?of?hepatitis?c?virus??
圖1-4酒精性肝病發(fā)展為肝癌的進程??
圖1-5非酒精性脂肪性肝病的發(fā)病機制??Fig.1-5?The?pathogenesis?of?nonalcoholic?fatty?liver?disease??
【參考文獻】:
期刊論文
[1]Targeted and immune therapies for hepatocellular carcinoma:Predictions for 2019 and beyond[J]. Masatoshi Kudo. World Journal of Gastroenterology. 2019(07)
[2]Hepatitis C virus core protein modulates several signaling pathways involved in hepatocellular carcinoma[J]. Shahab Mahmoudvand,Somayeh Shokri,Reza Taherkhani,Fatemeh Farshadpour. World Journal of Gastroenterology. 2019(01)
[3]Global elimination of hepatitis C virus infection: Progresses and the remaining challenges[J]. Reza Taherkhani,Fatemeh Farshadpour. World Journal of Hepatology. 2017(33)
[4]Functional interaction of endoplasmic reticulum stress and hepatitis B virus in the pathogenesis of liver diseases[J]. So Young Kim,Yi Yi Kyaw,Jaehun Cheong. World Journal of Gastroenterology. 2017(43)
[5]Role and regulation of the forkhead transcription factors FOXO3a and FOXM1 in carcinogenesis and drug resistance[J]. Ana R.Gomes,Fung Zhao,Eric W.F.Lam. Chinese Journal of Cancer. 2013(07)
[6]Adiponectin,a key adipokine in obesity related liver diseases[J]. Christa Buechler,Josef Wanninger,Markus Neumeier. World Journal of Gastroenterology. 2011(23)
本文編號:3349150
本文鏈接:http://sikaile.net/kejilunwen/jiyingongcheng/3349150.html
最近更新
教材專著